Chinese scientists developed a combined tumor-killing therapy that can be activated specifically at tumor sites in mouse models of cancer which is more effective than previous similar therapies. The study published on Friday in the journal Science Immunology described the new cancer immunotherapy that can prevent the immune system from becoming tolerant of tumors which occurs in 30 per cent of all cancer patients the Xinhua news agency reported. A team led by Wang Dangge from Shanghai Institute of Materia Medica under the Chinese Academy of Sciences and Fudan University developed a common immune checkpoint inhibitor in a nanoparticle formulation
